Oncology Corporate Profile
Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. Atara's lead programs target myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. In September 2014, Atara Biotherapeutics entered into an exclusive option agreement with MSK, under which it has the right to license (pursuant to a negotiated form of license agreement) the exclusive, worldwide rights to three clinical stage T-cell programs, including EBV-CTL, as well as other T-cell programs that are discovered or developed by MSK pursuant to sponsored research funded by the company.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|WT1-CTL||WT1 inhibitor||Multiple Myeloma||I|
|ATA129 (+ pembrolizumab)||EBV-specific cytotoxic T lymphocytes (CTL)||Nasopharyngeal cancer (NPC)||I||Merck|
|STM-434||Activin A inhibitor||Ovarian cancer||I|
|WT1-CTL||WT1 inhibitor||Plasma cell Leukemia (PCL)||I|
|STM-434||Activin A inhibitor||Various cancer types||I|
View additional information on product candidates here »
4/3/2017 12:00 pm
[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., April 03, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been ...
3/27/2017 09:00 pm
3/19/2017 04:04 pm
3/17/2017 04:04 pm
[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 17, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that ...
3/14/2017 05:00 pm
3/9/2017 01:03 pm
3/9/2017 01:03 pm